Evidence of disease control : a realistic concept beyond NEDA in the treatment of multiple sclerosis

Although no evidence of disease activity (NEDA) permits evaluation of response to treatment in the systematic follow-up of patients with multiple sclerosis (MS), its ability to accomplish detection of surreptitious activity of disease is limited, thus being unable to prevent patients from falling into a non-reversible progressive phase of disease. A protocol of evaluation based on the use of validated biomarkers that is conducted at an early stage of disease would permit the capture of abnormal neuroimmunological phenomena and lead towards intervention with modifying therapy before tissue damage has been reached. Carlos A. Mora ( ) Corresponding author: [email protected] Competing interests: CAM is a member of the Data & Safety Monitoring Board for the NINDS/NIH study NS003055-08/NS003056-08. He received no compensation for his participation in that study. ACL does not report any competing interests. Londoño AC and Mora CA. How to cite this article: Evidence of disease control: a realistic concept beyond NEDA in the treatment of 2017, :566 (doi: ) multiple sclerosis [version 1; referees: 2 approved] F1000Research 6 10.12688/f1000research.11349.1 © 2017 Londoño AC and Mora CA. This is an open access article distributed under the terms of the Copyright: Creative Commons Attribution , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Licence The author(s) declared that no grants were involved in supporting this work. Grant information: 25 Apr 2017, :566 (doi: ) First published: 6 10.12688/f1000research.11349.1 1